Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 (RAP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Duke University
Sponsor:
Collaborators:
NantCell, Inc.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Herbert Hurwitz, MD, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01061788
First received: February 2, 2010
Last updated: February 9, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2019
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)